Purple Biotech (PPBT) Operating Expenses (2014 - 2026)
Purple Biotech (PPBT) posted quarterly Operating Expenses of $2.3 million for Q1 2026, up 60.1% year-over-year from $1.4 million in Q1 2025, and down 24.06% quarter-over-quarter from $3.0 million in Q4 2025.
Purple Biotech (PPBT) Operating Expenses (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Operating Expenses for 12 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 60.1% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $7.8 million (changed 0.09% YoY), while the FY2025 annual figure was $27.5 million, up 149.5% from the prior year.
- Operating Expenses eased to $2.3 million in Q1 2026 per PPBT's latest filing, from $3.0 million in the prior quarter.
- Across five years, Operating Expenses topped out at $7.3 million in Q1 2022 and bottomed at $1.0 million in Q4 2024.
- Historically, Operating Expenses has averaged $3.8 million across 5 years, with a median of $3.6 million in 2022.
- Annual changes were most pronounced in 2024 — Operating Expenses tumbled 83.79% — and 2025, when it surged 191.73%.
- Purple Biotech's Operating Expenses stood at $6.6 million in 2022, then fell by 5.06% to $6.3 million in 2023, then sank by 83.79% to $1.0 million in 2024, then soared by 191.73% to $3.0 million in 2025, then dropped by 24.06% to $2.3 million in 2026.
- Business Quant data shows PPBT's Operating Expenses at $2.3 million in Q1 2026, $3.0 million in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Purple Biotech | 133.62 | 133.62 | - | 1.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.25 Mn |
| Dec 31, 2025 | 2.96 Mn |
| Sep 30, 2025 | 1.37 Mn |
| Jun 30, 2025 | 1.24 Mn |
| Mar 31, 2025 | 1.41 Mn |
| Dec 31, 2024 | 1.02 Mn |
| Sep 30, 2024 | 2.13 Mn |
| Jun 30, 2024 | 3.26 Mn |
| Mar 31, 2024 | 4.47 Mn |
| Dec 31, 2023 | 6.27 Mn |
| Sep 30, 2023 | 5.75 Mn |
| Jun 30, 2023 | 5.14 Mn |
| Mar 31, 2023 | 5.12 Mn |
| Dec 31, 2022 | 6.60 Mn |
| Sep 30, 2022 | 5.08 Mn |
| Jun 30, 2022 | 3.59 Mn |
| Mar 31, 2022 | 7.33 Mn |
| Dec 31, 2021 | 7.78 Mn |
| Sep 30, 2021 | 3.20 Mn |
| Jun 30, 2021 | 3.62 Mn |